Table 2.
Composite and Individual Outcome Rates according to the Optimal Bronchopulmonary Dysplasia Definition
| Outcome | No BPD (n = 773) | Grade 1 BPD (n = 1,038)* | Grade 2 BPD (n = 617) | Grade 3 BPD (n = 249) |
|---|---|---|---|---|
| Late death or serious respiratory morbidity† | 76 (10) | 199 (19) | 216 (35) | 192 (77) |
| Death after 36 wk PMA | 14 of 773 (2) | 25 of 1,038 (2) | 20 of 617 (3) | 50 of 249 (20) |
| Tracheostomy | 2 of 759 (0.3) | 7 of 1,013 (0.7) | 28 of 596 (5) | 62 of 199 (31) |
| NICU hospitalization beyond 50 wk PMA for respiratory reasons | 6 of 759 (0.8) | 25 of 1,013 (2) | 90 of 596 (15) | 101 of 199 (51) |
| Supplemental O2 use at follow-up | 6 of 759 (0.8) | 32 of 1,013 (3) | 52 of 596 (9) | 58 of 199 (29) |
| Ventilator or CPAP at follow-up | 4 of 759 (0.5) | 5 of 1,013 (0.5) | 18 of 596 (3) | 28 of 199 (14) |
| Respiratory monitor use at follow-up | 7 of 759 (0.9) | 41 of 1,013 (4) | 71 of 596 (12) | 81 of 199 (41) |
| ≥2 hospitalizations for respiratory reasons | 51 of 759 (7) | 132 of 1,013 (13) | 129 of 595 (22) | 57 of 199 (29) |
| Late death or moderate to severe NDI | 257 (33) | 480 (46) | 372 (60) | 196 (79) |
| Death after 36 wk PMA | 14 of 773 (2) | 25 of 1,038 (2) | 20 of 617 (3) | 50 of 249 (20) |
| Bayley-3 cognitive or motor composite score <85 | 173 of 757 (23) | 316 of 1,004 (31) | 260 of 585 (44) | 123 of 194 (63) |
| GMFCS level ≥2 | 36 of 759 (5) | 76 of 1,011 (8) | 93 of 597 (16) | 67 of 199 (34) |
| Blindness | 2 of 759 (0.3) | 12 of 1,012 (1) | 15 of 595 (3) | 12 of 198 (6) |
| Deafness | 14 of 759 (2) | 26 of 1,013 (3) | 17 of 595 (3) | 14 of 199 (7) |
Definition of abbreviations: Bayley-3 = Bayley Scales of Infant Development, Third Edition; BPD = bronchopulmonary dysplasia; CPAP = continuous positive airway pressure; GMFCS = Gross Motor Function Classification System; NDI = neurodevelopmental impairment; NICU = neonatal ICU; PMA = postmenstrual age.
Data are shown as n (%).
*
Includes 50 infants treated with supplemental oxygen administered by head box at 36 weeks’ PMA.
†
Data for nonmortality outcomes are shown for children who underwent follow-up at 18–26 months’ corrected age.